Trials / Completed
CompletedNCT04091945
A Study to Evaluate the Safety and Potential Efficacy of LT3001 Drug Product in Subjects With AIS
A Phase IIa, Double-Blind, Single Dose, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Potential Efficacy of LT3001 Drug Product in Subjects With Acute Ischemic Stroke (AIS)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Lumosa Therapeutics Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, double-blind, single-dose, randomized, and placebo-controlled prospective Phase IIa clinical study, designed to evaluate LT3001 drug product versus placebo/control in subjects with AIS.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LT3001 Drug Product | Active comparator |
| DRUG | Placebo | Placebo comparator |
Timeline
- Start date
- 2020-01-27
- Primary completion
- 2021-02-22
- Completion
- 2021-02-22
- First posted
- 2019-09-17
- Last updated
- 2026-01-22
- Results posted
- 2025-12-30
Locations
10 sites across 2 countries: United States, Taiwan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04091945. Inclusion in this directory is not an endorsement.